key: cord-0430070-kv2m2ww1
authors: Uckun, Fatih M.; Ozercan, Ibrahim H.; Orhan, Cemal; Gitterle, Marcus; Sahin, Kazim
title: Rejuveinix Reverses Severe Inflammatory Lung Damage in a Mouse Model of Fatal Sepsis
date: 2021-01-02
journal: bioRxiv
DOI: 10.1101/2020.12.31.424986
sha: bb9cd282c448a3a55ddfd53d25e26a1eb0002155
doc_id: 430070
cord_uid: kv2m2ww1

We set out to determine if our anti-sepsis drug candidate Rejuveinix (RJX) can effectively treat systemic inflammation in a mouse model of sepsis when used at a dose level that is >10-times lower than its maximum tolerated dose (MTD) for human subjects. Our findings obtained in the LPS-GalN mouse model of fatal sepsis provide experimental evidence that RJX exhibits potent single-agent anti-inflammatory activity and reverses very severe inflammatory lung injury when used therapeutically, thereby significantly improving the survival outcome. These findings demonstrate the clinical impact potential of RJX for the treatment of severe sepsis.

Severe viral sepsis caused by SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19), shows a rapid progression associated with a cytokine release syndrome (CRS) and a high case fatality rate due to the development of ARDS and multi-organ failure in high-risk COVID-19 patients (1, 2) . Our anti-sepsis drug candidate, Rejuveinix (RJX), is a rationally-designed formulation of naturally occurring antioxidants and anti-inflammatory compounds with a significant clinical impact potential for COVID-19 associated viral sepsis (3) (4) (5) . RJX showed a very favorable clinical safety profile in a recently completed double-blind, placebo-controlled, randomized, two-part, ascending dose-escalation Phase 1 study in healthy volunteers (Protocol No. RPI003; ClinicalTrials.gov Identifier: NCT03680105) (5). It has now entered a randomized double-blind, placebo-controlled Phase 2 study in hospitalized patients with critical COVID-19.

The goal of this research project was to determine if RJX can effectively treat systemic inflammation in a mouse model of sepsis. Our findings obtained in the LPS-GalN mouse model of fatal sepsis provide experimental evidence that RJX exhibits potent single-agent antiinflammatory activity and reverses very severe inflammatory lung injury when used therapeutically, thereby significantly improving the survival outcome. 

Here we report preclinical proof of concept data regarding the clinical impact potential of RJX for the treatment of sepsis. Specifically, we demonstrate that our anti-sepsis drug candidate RJX -at a dose level >10-fold lower than its clinical MTD-exhibits potent single-agent anti-inflammatory activity in the LPS-GalN mouse model of sepsis and multi-organ failure. It prevented inflammatory lung injury when used prophylactically and it reversed lung injury when used therapeutically, thereby significantly improving the survival outcome. The clinical potential of RJX is currently being examined in hospitalized COVID-19 patients with viral sepsis to test the hypothesis that will contribute to a faster resolution of respiratory failure and a reduced case mortality rate. A Phase II proof of concept study has also been designed to determine if RJX can favorably alter the clinical course and reduce the mortality rate of viral sepsis in critically ill COVID-19 patients.

The ingredients of RJX include ascorbic acid, magnesium sulfate heptahydrate, cyanocobalamin, thiamine hydrochloride, riboflavin 5' phosphate, niacinamide, pyridoxine hydrochloride, and calcium D-pantothenate. RJX is a two-vial system and A and B are each of the two vials. Vial A contains the active ingredients and minerals whereas Vial B contains the buffer, sodium bicarbonate as the Vial A content is acidic (5) .

The ability of RJX to prevent fatal shock, ARDS, and multi-organ failure was examined in the well-established LPS-GalN model (5) . The animal research study was approved by the Animal Care and Use Committee of Firat University. BALB/c mice were randomly divided into different treatment groups using pseudo-randomization convenience allocation and we applied the concealment of treatment allocation and blind outcome assessment to reduce the risk of 

Statistical analyses employed standard methods, including analysis of variance (ANOVA) and/or, nonparametric analysis of variance (Kruskal-Wallis) using the SPSS statistical program (IBM, SPPS Version 21), as reported (5) . Furthermore, the Kaplan-Meier method, log-rank chi-square test, was used to investigate survival and fatality in each group. 

Reducing the Fatality Rate of COVID-19 by Applying Clinical Insights From Immuno-Oncology and Lung Transplantation

Review of the Clinical Characteristics of Coronavirus Disease

Rationale For A Randomized, Placebo-Controlled, Phase 2 Study Of Rejuveinix (RJX) in COVID-19 Patients With Acute Lung Injury And Hypoxemic Respiratory Failure

Clinical Impact Potential Of Rejuveinix (RJX) For Prevention Of Fatal Acute Respiratory Distress Syndrome (ARDS) And Multi-Organ Failure

Rejuveinix Shows a Favorable Clinical Safety Profile in Human Subjects and Exhibits Potent Preclinical Protective Activity in the Lipopolysaccharide-Galactosamine Mouse Model of

Acute Respiratory Distress Syndrome and Multi-Organ Failure

Competing interests: F.M.U. is an employee of Reven Pharmaceuticals, the sponsor for the